CMGV for recurrent AML and high-risk MDS
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new treatment called CMGV for adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has returned or is not improving. It is for people who may be older or have had other blood disorders.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have acute myeloid leukemia (AML) or a higher-risk myelodysplastic syndrome (MDS-IB2) that has come back or is not responding to treatment.
- Your cancer is related to previous treatment, another blood disorder (like MDS or CMML), or certain gene changes. Or you are 60 or older.
- You are generally in good health (able to walk and do daily activities) with no major heart, liver, or kidney problems.
- You have not had mitoxantrone or too much of certain other chemotherapy drugs before.
- You do not have active hepatitis B or C, HIV, or a serious heart condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests mocravimod, added to standard care, to help keep acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow (stem cell) transplant. It may help by supporting long-term remission during the transplant recovery period.
This Phase 2 trial tests a new combination treatment (the “CAV regimen”) for people with relapsed or refractory acute myeloid leukemia (AML). It may help your body control leukemia again, especially if prior standard intensive treatments were not enough or the leukemia came back.
This trial tests a new drug combination called D-CMG for people aged 60–75 who have just been diagnosed with a type of leukemia (AML) and cannot have standard chemotherapy. The goal is to find a safe and effective dose.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This trial tests a new drug called GEN3018 for people with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
Hear when a new Recurrent Adult Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.